Navigation Links
Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
Date:10/7/2009

DUBLIN, October 7 /PRNewswire-FirstCall/ --

- For Medical and Healthcare Media Only -

- Direct Comparison of the Two non-Calcium Phosphate Binders Gives new Insights Into Relative Efficacy

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel(R)) in chronic kidney disease (CKD) patients on haemodialysis.

In this 12-week crossover study, patients (n=182) were randomized to receive either FOSRENOL or sevelamer for four weeks, and then switched to the alternative phosphate binder for the same period. Product doses were pre-defined to allow a direct efficacy comparison. Doses were based on those used in previous clinical trials[1,2] and established clinical practice.[3]

The study's primary endpoint, change in serum phosphorus from baseline to end of treatment, was evaluated using several statistical analyses; the primary analysis used last observation carried forward (LOCF) for the intention to treat (ITT) population (n=174), meaning that if a patient dropped out of the study during treatment, their last post baseline serum phosphorus measurement was used as the end of treatment value. The pre-determined key secondary analysis assessed the completer population; defined as those patients who had completed four weeks' treatment with both phosphate binders and had a serum phosphorus value at the end of treatment.[4]

The analysis of LOCF for the ITT population showed a numerically greater reduction in serum phosphorus with FOSRENOL (1.7mg/dL) versus sevelamer (1.4mg/dL), although
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. NASA study will help stop stowaways to Mars
7. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
10. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
11. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 18, 2014 The “Global Diagnostic ... Monitor), by End-user (Hospitals, Home/Ambulatory, Research Center, Physician ... 12) -Global Forecast to 2020” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:10/17/2014)... through the looking-glass to Wonderland, mirrors in the real ... including a new class of mirror that works like ... Optical Society,s (OSA) new high-impact journal Optica ... a new type of mirror that forgoes a familiar ... using an unusual magnetic property of a non-metallic metamaterial. ...
(Date:10/17/2014)... October 17, 2014 For the ... employers, as published in today’s print issue of ... annual Top Employers Survey polled employees in the ... 20 best employers. Rankings were determined based ... to rate their companies on 23 characteristics, including ...
(Date:10/17/2014)... The report "Advanced Utility Boiler Market by Type ... Super Critical Boilers, Low NOX Boilers, & Others), ... Power Plants, Clean Coal Technology Plants, & Others) ... 2019", defines and segments the global Advanced Boiler ... global revenue. , The advanced boiler market is ...
Breaking Biology Technology:The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 2The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 5Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4DuPont Named Top Employer by Science Magazine 2DuPont Named Top Employer by Science Magazine 3Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 2Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 3Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 4Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 5
... Watersports enthusiasts will soon be able to surf in ... The National Physical Laboratory (NPL) and UK wetsuit manufacturer, ... sports market. It approached NPL, the UK,s measurement institute, ... warm, to improve its product design. In particular it ...
... CAMBRIDGE, Massachusetts , May ... SHPGY ), the global specialty biopharmaceutical,company, today announced that ... from NORD. Shire was recognized for its efforts to ... enzyme replacement,therapy (ERT) for the treatment of Type 1 ...
... ATLANTA , May 19 Hothead ... to adapt the Sivix key computing fob and associated ... safety solutions.  These solutions are based upon the H.O.T.™ ... unit inside the helmet of an athlete, firefighter, soldier, ...
Cached Biology Technology:A warmer future for watersports 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 3Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 4Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 5Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 2Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 3
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... causes severe respiratory tract infections and worldwide claims ... at VIB and Ghent University have succeeded in ... common virus infection. , Xavier Saelens (VIB/UGent): ... the way for the development of a novel ... causes suffering in numerous small children and elderly ...
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... After a decade and a half of near stagnation, ... chronic illness instead of a terminal disease, a leading Colorado ... drugs have different and innovative methods of action. One is ... another is radiotherapy; and the final one is the first ...
... ingredient in the food industry because of its association with ... the February issue of the Journal of Food Science ... fish oil can be added to goat cheese to deliver ... or shelf-life. Fish oil delivers higher levels and more ...
... Republic of Congo has formally expanded Nouabal-Ndoki National Park ... most pristine forests and a population of "nave" chimpanzees ... apes investigate the conservationists who study them rather than ... 100-plus square-mile dense swamp forest and its unique great ...
Cached Biology News:4 new drugs will change prostate cancer care 2Great news for chimpanzees 2Great news for chimpanzees 3
...
... Marker consists of ten double-stranded RNAs, 10, ... 500 and 1,000 base pairs. The dsRNA ... determinating sizes of double-stranded RNAs. A twenty ... Marker is adjusted to approximately 25 ng/µl ...
... These protein size markers are a mixture ... 16 to 100 kDa. The markers provide ... gels after staining with Coomassie blue. Because ... II sequence, the markers can also be ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
Biology Products: